In a historic medical advance, the world’s first mRNA lung cancer vaccine trial has begun across seven countries, including the UK and the US. Developed by BioNTech, the BNT116 vaccine targets non-small cell lung cancer (NSCLC) by training the immune system to attack cancer cells. With 130 patients enrolled, this trial aims to revolutionize lung cancer treatment and reduce recurrence.